<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Arcellx Inc — News on 6ix</title>
    <link>https://6ix.com/company/arcellx-inc</link>
    <description>Latest news and press releases for Arcellx Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 17 Apr 2026 12:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/arcellx-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835421578dffbe2df0e121e.webp</url>
      <title>Arcellx Inc</title>
      <link>https://6ix.com/company/arcellx-inc</link>
    </image>
    <item>
      <title>Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer</title>
      <link>https://6ix.com/company/arcellx-inc/news/gilead-receives-all-required-regulatory-approvals-for-the-acquisition-of-arcellx-and-extends-tender-offer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/gilead-receives-all-required-regulatory-approvals-for-the-acquisition-of-arcellx-and-extends-tender-offer-1</guid>
      <pubDate>Fri, 17 Apr 2026 12:30:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., April 17, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.</description>
    </item>
    <item>
      <title>Gilead Extends Tender Offer to Acquire Arcellx</title>
      <link>https://6ix.com/company/arcellx-inc/news/gilead-extends-tender-offer-to-acquire-arcellx-7</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/gilead-extends-tender-offer-to-acquire-arcellx-7</guid>
      <pubDate>Wed, 01 Apr 2026 20:13:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., April 01, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject</description>
    </item>
    <item>
      <title>Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel</title>
      <link>https://6ix.com/company/arcellx-inc/news/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel-1</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel-1</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma – – FDA Accepted Anito-cel</description>
    </item>
    <item>
      <title>Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-announces-late-breaking-presentation-tandem-demonstrating-unique-high-target</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-announces-late-breaking-presentation-tandem-demonstrating-unique-high-target</guid>
      <pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
      <description>-- CAR constructs representative of anito-cel (D-Domain), cilta-cel (dual VHH), and ide-cel (scFv) were assessed preclinically for tonic signaling and</description>
    </item>
    <item>
      <title>Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-advance-conversation-its-platform-and-importance-early-car-t-access-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-advance-conversation-its-platform-and-importance-early-car-t-access-patients</guid>
      <pubDate>Wed, 21 Jan 2026 05:00:00 GMT</pubDate>
      <description>-- The D-Domain binder has a fast off-rate and contributes to anito-cel’s differentiated pharmacology profile in multiple myeloma -- -- A simulation model of</description>
    </item>
    <item>
      <title>Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-announces-new-positive-data-its-immagine-1-study-patients-relapsed-and-or</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-announces-new-positive-data-its-immagine-1-study-patients-relapsed-and-or</guid>
      <pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
      <description>-- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6</description>
    </item>
    <item>
      <title>Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-host-investor-relations-event-during-67th-ash-annual-meeting-and-exposition</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-host-investor-relations-event-during-67th-ash-annual-meeting-and-exposition</guid>
      <pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
      <description>Saturday, December 6, 2025 at 8:00 p.m. ET REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell</description>
    </item>
    <item>
      <title>Arcellx Provides Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-provides-third-quarter-2025-financial-results-2025-11-05</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-provides-third-quarter-2025-financial-results-2025-11-05</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative</description>
    </item>
    <item>
      <title>Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-present-new-data-its-immagine-1-study-and-continues-scientific-momentum</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-present-new-data-its-immagine-1-study-and-continues-scientific-momentum</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>-- A more recent data cut will be shared during an oral presentation for the iMMagine-1 study -- -- To date, no delayed neurotoxicities, including no</description>
    </item>
    <item>
      <title>Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-participate-2025-morgan-stanley-global-healthcare-conference-2025-09-03</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-participate-2025-morgan-stanley-global-healthcare-conference-2025-09-03</guid>
      <pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative</description>
    </item>
    <item>
      <title>Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-provides-second-quarter-2025-financial-results-and-business-highlights-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-provides-second-quarter-2025-financial-results-and-business-highlights-2025</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>-- Presented preliminary data from a May 1, 2025 data cutoff date for all 117 patients with a median follow-up of 12.6 months in the Phase 2 pivotal</description>
    </item>
    <item>
      <title>Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-announces-its-participation-td-cowens-6th-annual-oncology-innovation-summit</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-announces-its-participation-td-cowens-6th-annual-oncology-innovation-summit</guid>
      <pubDate>Wed, 21 May 2025 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative</description>
    </item>
    <item>
      <title>Arcellx Provides First Quarter 2025 Financial Results and Business Highlights</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-provides-first-quarter-2025-financial-results-and-business-highlights-2025-05</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-provides-first-quarter-2025-financial-results-and-business-highlights-2025-05</guid>
      <pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
      <description>-- iMMagine-1 data accepted for Oral Presentation at EHA -- -- iMMagine-3 study updated to include MRD negativity as a dual primary endpoint -- -- Added two</description>
    </item>
    <item>
      <title>Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-appoints-andrew-galligan-and-kristin-myers-its-board-directors-2025-03-20</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-appoints-andrew-galligan-and-kristin-myers-its-board-directors-2025-03-20</guid>
      <pubDate>Thu, 20 Mar 2025 04:00:00 GMT</pubDate>
      <description>-- Mr. Galligan and Ms. Myers bring decades of experience to the company board -- -- Derek Yoon steps down from the Board of Directors -- REDWOOD CITY,</description>
    </item>
    <item>
      <title>Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-provides-fourth-quarter-and-year-end-2024-financial-results-and-business</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-provides-fourth-quarter-and-year-end-2024-financial-results-and-business</guid>
      <pubDate>Thu, 27 Feb 2025 05:00:00 GMT</pubDate>
      <description>-- Presented positive preliminary data at ASH 2024 from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel in patients with RRMM which</description>
    </item>
    <item>
      <title>Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-participate-td-cowen-45th-annual-health-care-conference-2025-02-26</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-participate-td-cowen-45th-annual-health-care-conference-2025-02-26</guid>
      <pubDate>Wed, 26 Feb 2025 05:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative</description>
    </item>
    <item>
      <title>Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-announces-new-positive-data-its-immagine-1-study-patients-relapsed-or</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-announces-new-positive-data-its-immagine-1-study-patients-relapsed-or</guid>
      <pubDate>Sun, 08 Dec 2024 05:00:00 GMT</pubDate>
      <description>-- Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median</description>
    </item>
    <item>
      <title>Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-provides-third-quarter-2024-financial-results-and-business-highlights-2024-11</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-provides-third-quarter-2024-financial-results-and-business-highlights-2024-11</guid>
      <pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
      <description>-- Recently released ASH abstracts for the company’s Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma</description>
    </item>
    <item>
      <title>Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-present-clinical-data-its-phase-1-and-immagine-1-studies-patients-relapsed-or</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-present-clinical-data-its-phase-1-and-immagine-1-studies-patients-relapsed-or</guid>
      <pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
      <description>-- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached</description>
    </item>
    <item>
      <title>Arcellx Provides Second Quarter 2024 Financial Results and Business Updates</title>
      <link>https://6ix.com/company/arcellx-inc/news/arcellx-provides-second-quarter-2024-financial-results-and-business-updates-2024-08</link>
      <guid isPermaLink="true">https://6ix.com/company/arcellx-inc/news/arcellx-provides-second-quarter-2024-financial-results-and-business-updates-2024-08</guid>
      <pubDate>Thu, 08 Aug 2024 04:00:00 GMT</pubDate>
      <description>-- Earned a $68M milestone payment from Kite for iMMagine-1 enrollment -- -- Submitted an abstract for the iMMagine-1 study at the 66th ASH Annual Meeting --</description>
    </item>
  </channel>
</rss>